Brief: Oncopeptides Secures Fast-Track Designation In Glioblastoma
09/03/2026 07:34
March 9 (Reuters) - Oncopeptides AB ONCO.ST: ONCOPEPTIDES: ONCOPEPTIDES SECURES FAST-TRACK DESIGNATION FOR WINDOW-OF-OPPORTUNITY STUDY IN GLIOBLASTOMA ANNOUNCES REGULATORY AGREEMENT WITH SWEDISH AND NORWEGIAN MEDICAL PRODUCTS AGENCIES GLOBAL GLIOBLASTOMA MARKET ESTIMATED TO EXCEED $8 BILLION IN 2035 Source text: ID:nMFN5jSJPB Further company coverage: ONCO.ST (Gdansk Newsroom) ((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Oncopeptides AB
See all newsSweden's Oncopeptides Q3 net sales rise on Pepaxti demand
Brief: Oncopeptides Q3 Operating Profit SEK -36.47 Million
Brief: Oncopeptides Completes Directed Share Issue Of SEK 100 Mln
Brief: Oncopeptides Confirms Blood-Brain-Barrier Penetration In Glioblastoma Study
Swedish biotech Oncopeptides' Q2 net sales rise on strong demand in Italy